Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

September 30, 2026

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

Performance

52-Week Range 34.7% below 52-week high

4.560

3.2052W Low 6.9852W High

1 Week 8.6% below 1-week high

4.521W Low 4.991W High

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (LSE) traded between $3.20 and $6.98 over the past 52 weeks and last traded at $4.56, 34.7% below its 52-week high. Over the past week it ranged between $4.52 and $4.99.

Past 12 Months

-8.6%

-14.5%

+7.3%

-4.0%

+6.8%

-18.7%

1W -$0.43

1M -$0.78

3M +$0.31

6M -$0.19

YTD +$0.29

1Y -$1.05

LSE was -18.7% over the past year, -4.0% over six months, +6.8% year to date, -8.6% in the last week.

12 Months vs Market

LSE

-18.7%

DIA

+12.4%

SPY

+14.9%

QQQ

+17.5%

IWM

+11.1%

Over the past 12 months LSE returned -18.7% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.12× 3-mo avg

Today 758 3-mo avg 6.6K

2.6K

5.6K

6.6K

10.7K

YTD

12.3K

10.7K

LSE most recently traded 758 shares against a 3-month average daily volume of 6.6K.

More News

September 28, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

September 27, 2026

Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer

September 25, 2026

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

September 23, 2026

The Elmet Group Secures Long-Term Tungsten Offtake Agreement with Tungsten West’s Hemerdon Mine

September 22, 2026

From The Elmet Group

Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial

September 16, 2026

Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee

September 14, 2026

PPHC Increases 2026 Interim Dividend to $0.117 Per Share

September 11, 2026

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

September 03, 2026

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

August 30, 2026

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

August 27, 2026

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

August 16, 2026

Public Policy Holding Company, Inc. Announces Q2 2026 Financial Results

August 10, 2026

TierPoint Launches Adapt DDoS Protection

August 04, 2026

From TierPoint

PPHC Acquires Florida Government Relations Firm

August 03, 2026

HUTCHMED Reports 2026 Interim Results

July 30, 2026

PPHC to Report Second Quarter 2026 Financial Results and Present at Upcoming Investor Conference

July 27, 2026

PPHC Strengthens Public Affairs Offering with Hire of Managing Director and Content Specialist

July 14, 2026

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

July 08, 2026

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

July 02, 2026

PPHC Announces Acquisition of Tancredi

July 01, 2026

HUTCHMED to Announce 2026 Half-Year Financial Results

June 30, 2026

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

June 26, 2026

From Virtual Investor Conferences